Use of cookies by
Norton Rose Group
We use cookies to deliver our online services. Details and instructions on how to disable those cookies are set out here. By continuing to use this website you agree to our use of our cookies unless you have disabled them.

Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products
January 2012

The Norton Rose Canada LLP Guide to the "Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products" provides a brief historical survey of the legislative protection extended to innovative drug products in Canada, including a consideration of Canada's international treaty obligations respecting IP rights.

Download Evolution of Canadian Intellectual Property Legislation Affecting Innovative Drug Products (pdf 431kb)

Back to top

Related contacts

Patrick Kierans

Patrick E. Kierans

Head of Pharmaceuticals and Life Sciences, Senior Partner

Toronto (Royal Bank Plaza)

+1 416.216.3904

Judith Robinson

Judith Robinson

Partner, Lawyer, Trade-mark Agent

Montréal

+1 514.847.4608

Brian Daley

Brian R. Daley

Partner, Lawyer, Trade-mark Agent

Montréal

+1 514.847.4764

Key industry sectors